Jubilant Organosys, the Indian pharma company focused on contract research and manufacturing services (CRAMS), is strengthening its position in active pharmaceuticals ingredient (API) business and expanding its API product portfolio to 100+ products by 2012-13. The company also plans to increase global presence by expanding its base from 45 to 60 countries, officials said in an analyst meet held in Mumbai. The company has kept an investment of Rs 100 crore to commercialise new products.
According to Jubilant Organosys chairman and managing director Shyam S Bhartia, the company has been exploring a strategy of identifying products ahead of competition for ?first to offer? opportunity.? It has plans to enter into new segment with high potency such as injectables APIs.
The company has filed drug master files (DMFs) for 32 products in Europe and the US while for 21 products in Canada. The company claims to have a global leadership in products such as Carbamazepine, Oxcarbazepine, Lamotrigine, Citalopram and Risperidone.
